Equities

Sareum Holdings PLC

SAR:LSE

Sareum Holdings PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)17.00
  • Today's Change0.00 / 0.00%
  • Shares traded17.53k
  • 1 Year change-12.82%
  • Beta-0.0009
Data delayed at least 20 minutes, as of Feb 06 2026 16:24 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Sareum Holdings plc is a United Kingdom-based clinical-stage biotechnology company. The principal activity of the Company is the discovery and development of new therapeutic drugs using a combination of skills in biology, computational chemistry and medicinal chemistry. The Company is focused on advancing inhibitors of the JAK kinase family into clinical development for autoimmune disease and cancer. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, including psoriasis, and has completed Phase 1 clinical development. The Company is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy. Additionally, the Company owns the license for SRA737, a clinical-stage oral, selective Checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA damage repair mechanisms.

  • Revenue in GBP (TTM)0.00
  • Net income in GBP-4.44m
  • Incorporated2004
  • Employees5.00
  • Location
    Sareum Holdings PLCUnit 2ALangford Arch, London Road, PampisfordCAMBRIDGE CB22 3FXUnited KingdomGBR
  • Phone+44 12 2349 7700Fax+44 12 2349 7701
  • Websitehttps://sareum.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Cizzle Biotechnology Holdings PLC0.00-1.12m6.14m67.006.14m67.00
Futura Medical PLC7.93m-6.29m7.41m12.007.41m12.00
OptiBiotix Health PLC1.15m-191.00k7.90m5.007.90m5.00
IXICO PLC6.53m-1.65m9.50m79.009.50m79.00
Genflow Biosciences PLC0.00-1.80m10.86m5.0010.86m5.00
Solvonis Therapeutics PLC0.00-2.60m16.34m--16.34m--
Fusion Antibodies PLC1.60m-1.47m19.07m24.0019.07m24.00
Sareum Holdings Plc0.00-4.44m23.47m5.0023.47m5.00
Arecor Therapeutics PLC5.06m-8.10m29.26m37.0029.26m37.00
Poolbeg Pharma PLC0.00-5.71m30.68m10.0030.68m10.00
ImmuPharma PLC0.00-3.93m32.73m6.0032.73m6.00
hVIVO PLC51.28m5.28m41.91m301.0041.91m301.00
Data as of Feb 06 2026. Currency figures normalised to Sareum Holdings PLC's reporting currency: UK Pound GBX

Institutional shareholders

12.69%Per cent of shares held by top holders
HolderShares% Held
Hargreaves Lansdown Fund Managers Ltd.as of 01 Oct 20257.96m5.76%
HSBC Global Asset Management (UK) Ltd.as of 01 Oct 20256.14m4.45%
KW Investment Management Ltd.as of 01 Oct 20251.26m0.91%
IG Markets Ltd.as of 01 Oct 2025717.00k0.52%
Eurizon Capital SGR SpAas of 01 Oct 2025404.00k0.29%
Rowan Dartington & Co. Ltd. (Broker)as of 01 Oct 2025278.00k0.20%
Evelyn Partners Investment Management Services Ltd.as of 01 Oct 2025241.00k0.18%
HSBC Bank Plc (Market-Maker)as of 01 Oct 2025207.00k0.15%
Rathbones Investment Management Ltd.as of 01 Oct 2025182.00k0.13%
J. M. Finn & Co. Ltd.as of 01 Oct 2025129.00k0.09%
More ▼
Data from 31 Jan 2025 - 02 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.